Second Interim Analysis (ia2) Results from A Phase Ii Trial of Tak-385, an Oral Gnrh Antagonist, in Prostate Cancer Patients (Pts).
JOURNAL OF CLINICAL ONCOLOGY（2016）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined